原发肿瘤切除联合化疗对比单纯化疗治疗结直肠癌无症状同步不可切除转移:JCOG1007随机临床试验
这项随机III期研究比较原发肿瘤切除后化疗与单纯化疗在无症状同步不可切除转移性结直肠癌患者中的总生存,因无效提前终止;中位随访22.0个月,两组中位OS分别为25.9个月和26.7个月,无生存获益,原发肿瘤切除不应再作为标准治疗。
要点
- 原发肿瘤切除联合化疗未改善无症状同步不可切除转移性结直肠癌的总生存。
- 研究因无效提前终止,原发肿瘤切除不应再作为该类患者的标准治疗。
- 原发肿瘤切除组出现3例术后死亡。
核心结论
- 原发肿瘤切除后化疗对比单纯化疗未显示生存获益,原发肿瘤切除不应再被视为无症状原发肿瘤伴同步不可切除转移的结直肠癌患者的标准治疗。
研究设计与样本
- 随机III期研究,纳入不可切除IV期无症状结直肠癌且转移灶限于肝、肺、远处淋巴结或腹膜且不超过3个的患者。
- 共165例患者随机分配至单纯化疗组84例或原发肿瘤切除联合化疗组81例。
- 化疗方案在研究入组前决定,为mFOLFOX6联合贝伐珠单抗或CapeOX联合贝伐珠单抗。
- 主要终点为总生存,采用意向性治疗分析。
主要发现
- 中位随访22.0个月,原发肿瘤切除联合化疗组中位OS为25.9个月(95% CI 19.9至31.5),单纯化疗组为26.7个月(95% CI 21.9至32.5)。
- 原发肿瘤切除联合化疗组发生3例术后死亡。
- 2019年9月第一次 interim 分析时观察到预期事件的50%(114/227),数据与安全监查委员会因无效建议提前终止试验。
临床怎么用
- 对于无症状原发肿瘤且同步不可切除转移的结直肠癌患者,不应常规进行原发肿瘤切除。
- 此类患者可考虑单纯化疗作为标准治疗策略。
局限性
- 研究因无效提前终止,实际事件数少于预期。
- 中位随访时间较短(22.0个月)。
- 原发肿瘤切除组出现3例术后死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: It remains controversial whether primary tumor resection (PTR) before chemotherapy improves survival in patients with colorectal cancer (CRC) with asymptomatic primary tumor and synchronous unresectable metastases. PATIENTS AND METHODS: This randomized phase III study investigated the superiority of PTR followed by chemotherapy versus chemotherapy alone in relation to overall survival (OS) in patients with unresectable stage IV asymptomatic CRC and three or fewer unresectable metastatic diseases confined to the liver, lungs, distant lymph nodes, or peritoneum. Chemotherapy regimens of either mFOLFOX6 plus bevacizumab or CapeOX plus bevacizumab were decided before study entry. The primary end point was OS, which was analyzed by intention-to-treat. RESULTS: Between June 2012 and September 2019, a total of 165 patients were randomly assigned to either chemotherapy alone (84 patients) or PTR plus chemotherapy (81 patients). When the first interim analysis was performed in September 2019 with 50% (114/227) of the expected events observed among 160 patients at the data cutoff date of June 5, 2019, the Data and Safety Monitoring Committee recommended early termination of the trial because of futility. With a median follow-up of 22.0 months, median OS was 25.9 months (95% CI, 19.9 to 31.5) in the PTR plus chemotherapy arm and 26.7 (95% CI, 21.9 to 32.5) in the chemotherapy-alone arm (hazard ratio, 1.10; 95% CI, 0.76 to 1.59; one-sided P = .69). Three postoperative deaths occurred in the PTR plus chemotherapy arm. CONCLUSION: Given that PTR followed by chemotherapy showed no survival benefit over chemotherapy alone, PTR should no longer be considered a standard of care for patients with CRC with asymptomatic primary tumors and synchronous unresectable metastases.
引用
- Kanemitsu Y, Shitara K, Mizusawa J, et al. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. J Clin Oncol. 2021. PMID: 33560877. doi:10.1200/JCO.20.02447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。